221 related articles for article (PubMed ID: 34740331)
1. Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial.
Italiano A; Dinart D; Soubeyran I; Bellera C; Espérou H; Delmas C; Mercier N; Albert S; Poignie L; Boland A; Bourdon A; Geneste D; Cavaille Q; Laizet Y; Khalifa E; Auzanneau C; Squiban B; Truffaux N; Olaso R; Gerber Z; Wallet C; Bénard A; Blay JY; Laurent-Puig P; Deleuze JF; Lucchesi C; Mathoulin-Pelissier S;
BMC Cancer; 2021 Nov; 21(1):1180. PubMed ID: 34740331
[TBL] [Abstract][Full Text] [Related]
2. Is There Value in Molecular Profiling of Soft-Tissue Sarcoma?
Italiano A
Curr Treat Options Oncol; 2018 Dec; 19(12):78. PubMed ID: 30523434
[TBL] [Abstract][Full Text] [Related]
3. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
4. Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial.
Filleron T; Le Guellec S; Chevreau C; Cabarrou B; Lesluyes T; Lodin S; Massoubre A; Mounier M; Poublanc M; Chibon F; Valentin T
BMC Cancer; 2020 Jul; 20(1):716. PubMed ID: 32736540
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics.
Jour G; Scarborough JD; Jones RL; Loggers E; Pollack SM; Pritchard CC; Hoch BL
Hum Pathol; 2014 Aug; 45(8):1563-71. PubMed ID: 24908143
[TBL] [Abstract][Full Text] [Related]
6. The clinical utility of next-generation sequencing for bone and soft tissue sarcoma.
Gusho CA; Weiss MC; Lee L; Gitelis S; Blank AT; Wang D; Batus M
Acta Oncol; 2022 Jan; 61(1):38-44. PubMed ID: 34686105
[No Abstract] [Full Text] [Related]
7. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Evaluating parents' decisions about next-generation sequencing for their child in the NC NEXUS (North Carolina Newborn Exome Sequencing for Universal Screening) study: a randomized controlled trial protocol.
Milko LV; Rini C; Lewis MA; Butterfield RM; Lin FC; Paquin RS; Powell BC; Roche MI; Souris KJ; Bailey DB; Berg JS; Powell CM
Trials; 2018 Jun; 19(1):344. PubMed ID: 29950170
[TBL] [Abstract][Full Text] [Related]
10. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
11. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
13. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
Andersson C; Fagman H; Hansson M; Enlund F
Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of high-throughput sequencing in clinical routine cancer care: lessons from the cancer pilot project of the France Genomic Medicine 2025 plan.
; Auzanneau C; Bacq D; Bellera C; Blons H; Boland A; Boucheix M; Bourdon A; Chollet E; Chomienne C; Deleuze JF; Delmas C; Dinart D; Espérou H; Geillon F; Geneste D; Italiano A; Jean D; Khalifa E; Laizet Y; Laurent-Puig P; Lethimonnier F; Lévy-Marchal C; Lucchesi C; Malle C; Mancini P; Mathoulin-Pélissier S; Meyer V; Marie-Ange P; Perkins G; Sellan-Albert S; Soubeyran I; Wallet C
ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32713836
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study.
Hara H; Kawamoto T; Fukase N; Kawakami Y; Takemori T; Fujiwara S; Kitayama K; Nishida K; Kuroda R; Akisue T
BMC Cancer; 2019 Jul; 19(1):725. PubMed ID: 31337342
[TBL] [Abstract][Full Text] [Related]
16. The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments.
Blay JY; Le Cesne A; Demetri GD
Expert Rev Anticancer Ther; 2020 Apr; 20(sup1):29-39. PubMed ID: 32349562
[No Abstract] [Full Text] [Related]
17. [The necessity and urgency of molecular analysis in the diagnosis and treatment of bone and soft tissue sarcomas].
Niu XH; Xu HR
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2399-2404. PubMed ID: 36000368
[TBL] [Abstract][Full Text] [Related]
18. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
[TBL] [Abstract][Full Text] [Related]
19. What Would Next Generation Sequencing Bring to the Diagnosis and Treatment of Sarcomas? A Series of 20 Cases, a Single Institution's Experience.
Kulaç İ; Bulutay P; Meriçöz ÇA
Turk Patoloji Derg; 2021; 37(3):226-232. PubMed ID: 34514574
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
